Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes

被引:32
作者
Mu, Pan-wei [1 ]
Chen, Yan-ming [1 ]
Lu, Hong-yun [2 ]
Wen, Xing-qiao [3 ]
Zhang, Yan-hua [1 ]
Xie, Ru-ying [1 ]
Shu, Jiong [1 ]
Wang, Man-man [1 ]
Zeng, Long-yi [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Endocrinol, Guangzhou 510630, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Endocrinol, Zhuhai, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Urol, Guangzhou 510630, Guangdong, Peoples R China
关键词
ss-cell function; glycaemic remission; basal insulin; type; 2; diabetes; early intensive control; RESISTANCE; STRATEGIES; INDUCTION; GLUCOSE; FAILURE; OBESE;
D O I
10.1002/dmrr.1292
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Oral anti-diabetes drugs plus basal insulin (OAD+ insulin) therapy in patients with newly diagnosed type 2 diabetes might improve beta-cell function and result in extended glycaemic remission. This randomised trial compared the effect on beta-cell function and diabetes remission rate between oral drug alone or with addition of basal insulin. Methods One hundred and twenty-nine patients, aged 35-50 years, were enrolled between June 2005 and June 2009. For initial correction of hyperglycaemia, patients with fasting plasma glucose >= 9.0 mmol/L and HbA(1c) >= 9.0%, were randomly assigned to therapy with oral drugs+ insulin or oral drugs alone. Treatment was stopped after normoglycaemia was maintained for 3 months. Patients were then followed-up with diet and physical exercise. Blood glucose, HbA(1c) and insulin were measured prior to treatment and at 1-year follow-up. Results More patients achieved target glycaemic control in the oral drugs+ insulin group [98.3% (58 of 59)] in less time [(10.4 +/- 2.5) days] than those in the oral drug group [95.7% (67 of 70) and (12.4 +/- 3.4) days]. At 1-year follow-up, more patients maintained target glycaemia without any drugs in the oral drug+ insulin group than in the oral drug group [37.9% (22 of 58) vs 20.9% (14 of 67)]. Both treatments improved homeostasis model assessment-beta (HOMA-beta) and homeostasis model assessment-insulin resistance (HOMA-IR) significantly. They had similar effects on insulin resistance [lg(HOMA-IR): (0.50 +/- 0.09) vs (0.48 +/- 0.09), p= 0.23]. However, oral drugs+ insulin could recover beta-cell function much more than OAD alone could [lg(HOMA-beta): (2.17 +/- 0.14) vs (2.11 +/- 0.13), p= 0.03]. Conclusion In newly diagnosed type 2 diabetes, therapywith oral drugs+ insulin has had favourable outcomes on recovery and maintenance of beta-cell function and protracted glycaemic remission compared with treatment with oral drugs alone. Copyright c 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:236 / 240
页数:5
相关论文
共 21 条
  • [1] Type 2 diabetes, insulin secretion and β-cell mass
    Ahrén, B
    [J]. CURRENT MOLECULAR MEDICINE, 2005, 5 (03) : 275 - 286
  • [2] Cefalu WT, 2002, AM J MED, V113, p23S
  • [3] Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes
    Cryer, PE
    [J]. DIABETOLOGIA, 2002, 45 (07) : 937 - 948
  • [4] The Role of Adipose Tissue and Lipotoxicity in the Pathogenesis of Type 2 Diabetes
    Cusi, Kenneth
    [J]. CURRENT DIABETES REPORTS, 2010, 10 (04) : 306 - 315
  • [5] Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects:: Evidence for an anti-inflammatory effect?
    Dandona, P
    Aljada, A
    Mohanty, P
    Ghanim, H
    Hamouda, W
    Assian, E
    Ahmad, S
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (07) : 3257 - 3265
  • [6] MECHANISM OF METFORMIN ACTION IN OBESE AND LEAN NONINSULIN-DEPENDENT DIABETIC SUBJECTS
    DEFRONZO, RA
    BARZILAI, N
    SIMONSON, DC
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (06) : 1294 - 1301
  • [7] A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study
    Gerstein, H. C.
    Yale, J. -F.
    Harris, S. B.
    Issa, M.
    Stewart, J. A.
    Dempsey, E.
    [J]. DIABETIC MEDICINE, 2006, 23 (07) : 736 - 742
  • [8] Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment
    Ilkova, H
    Glaser, B
    Tunckale, A
    Bagriacik, N
    Cerasi, E
    [J]. DIABETES CARE, 1997, 20 (09) : 1353 - 1356
  • [9] Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function
    Li, YB
    Xu, W
    Liao, ZH
    Yao, B
    Chen, XH
    Huang, ZM
    Hu, GL
    Weng, JP
    [J]. DIABETES CARE, 2004, 27 (11) : 2597 - 2602
  • [10] HOMEOSTASIS MODEL ASSESSMENT - INSULIN RESISTANCE AND BETA-CELL FUNCTION FROM FASTING PLASMA-GLUCOSE AND INSULIN CONCENTRATIONS IN MAN
    MATTHEWS, DR
    HOSKER, JP
    RUDENSKI, AS
    NAYLOR, BA
    TREACHER, DF
    TURNER, RC
    [J]. DIABETOLOGIA, 1985, 28 (07) : 412 - 419